Barely an hour after being wheeled into a clinical space at Oregon Health & Science University on Aug. 27, an Arkansas woman emerged with vastly improved symptoms of the Parkinson's disease that had ...

The NIH has awarded a $3 million research grant to CND Life Sciences to initiate a 3-year multicenter study to evaluate the validity of a skin punch biopsy test to determine risk for Parkinson’s ...

Investors looking for stocks that can produce eye-popping gains in a short time frame often turn toward biotechnology stocks. In this wonky industry, encouraging results from a clinical trial can turn ...

Transcutaneous afferent patterned stimulation is linked to metabolic activity changes in the cerebellum and other brain areas ...

The company plans to conduct a three-year study of Parkinson's risk among people with essential tremor, using its Syn-One Test.

DelveInsight’s “Essential Tremor Pipeline Insight 2025” report provides comprehensive insights about 7+ companies and 10+ pipeline drugs in the Essential Tremor pipeline landscape. It covers the ...

Bolstered by a late-stage trial win for its essential tremor drug, Praxis Precision Medicines Inc. is looking to raise $525 million in a public offering.

Praxis Precision Medicines said patients with a condition that causes uncontrollable shaking saw improvement using its experimental drug.

Praxis Precision Medicines shares more than doubled in premarket trading Thursday after the clinical-stage biopharmaceutical reported positive topline results from a pair of late-stage studies of its ...

Praxis Precision Medicines’ commitment to forging ahead with ulixacaltamide in essential tremor (ET) has paid off. After brushing off a recommendation to end a phase 3 study earlier this year based on ...